the patient, the rate of spinal anesthetic agent injection, intravenous fluid loading, and whether the women is laboring or has associated morbidity such as pregnancy induced hypertension. Regardless of the definition and associated factors that change the incidence of hypotension, this phenomenon is common enough that all anesthesiologists must be vigilant during cesarean delivery performed under spinal anesthesia. ' 
Physiology of Postspinal Hypotension
The recommended dose of hyperbaric bupivacaine to achieve predictable anesthetic effect for cesarean delivery appears to be between 12.5 to 15 mg, depending upon whether lipophilic narcotics are added. 2 With this dose, a block extends above the thoracic upper limit of the autonomic nervous system, and effectively removes sympathetic control of the cardiovascular system. The induced sympathectomy causes vasodilation with a subsequent decrease in systemic vascular resistance (SVR). The decrease in SVR will compound the parturient's predisposition to hypotension in the supine position.
The supine hypotensive syndrome was first reported in the 1930's by a Swedish obstetrician, Gideon Ahltorp, who perceptively observed the event and identified mechanical treatments including the prone position, manual displacement of the uterus to the left, and immersion of the body in water to the neck. 3 Approximately 2.5% to 20.6% (mean of 8%) of pregnant women, evaluated during the second and third trimester, will develop the syndrome when positioned supine. Frank Holmes, a consultant anesthetist in Edinburgh, Scotland described the implications of supine hypotension when combined with anesthesia, particularly regional anesthesia. 4 He noted spinal anesthesia's ability to ''reduce cardiac output to a dangerous degree'' and that accompanying hypotension likely contributed to maternal deaths occurring during cesarean delivery. An electronic search of a medical database using terms spinal anesthesia+ maternal death led to more than 10 website pages of publications. In light of this predictable event, anesthesiologists must be prepared to prevent maternal hypotension, and to treat it quickly if it does occur. ' 
Vasopressor Therapy
Despite maneuvers such as slow injection of spinal local anesthetics, administration of colloid intravenous fluid bolus, and the use of compressive leg devices, anesthesiologists will have to treat with vasopressor medications 40% to 60% of women undergoing cesarean delivery. The choice of vasopressors in North America includes ephedrine, phenylephrine, and epinephrine. Other sympathomimetics are available, such as methoxamine, mephentermine, dopamine, and norepinephrine; however, their use is uncommon with obstetric regional anesthesia. One sympathomimetic not used in North America but used widely elsewhere is metaraminol. The ideal vasopressor is inexpensive, easily available, quick in onset, reliable, favorably affects maternal heart rate and minimizes detrimental effects upon the fetus and placental perfusion. The choice between ephedrine and phenylephrine has provoked much debate. The advantages and disadvantages of each will be discussed in the next sections.
'
Vasopressor Basic Science
Structure and Metabolism
The key element common to all vasopressors is their ability to mimic some of the sympathetic nervous system activities. The differences between them depend upon each drug's ability to lead to a and breceptor stimulation. The pharmacologic activity of each vasopressor is dependent upon its structural configuration. 5 The basic structure of all sympathomimetics is the benzene-ring based b-phenylethylamine (Fig. 1) .
a and b-receptor activity is maximized if hydroxyl groups are attached at the third and fourth carbons of the benzene ring. Compounds without hydroxyl groups on the third and fourth carbon are synthetic noncatecholamines. Included in this group are ephedrine and phenylephrine.
The metabolism of phenylephrine is by the same process as the natural and synthetic catecholamines, which is rapid inactivation by catchol-O-methyltranserease and monamine oxidase. Because of its short duration of action, it can be administered by intravenous boluses of 50 to 200 mcg, or by intravenous infusion of 20 to 50 mcg/min. Ephedrine is not metabolized by catchol-O-methyltranserease enzymes because it lacks hydroxyl groups, and monamine oxidase enzyme deamination does not occur because of its a-methyl group. Thus, ephedrine is excreted almost unchanged in urine. Its actions are primarily ended by reuptake in terminal nerve endings. This difference in metabolism explains the relatively long duration of action of ephedrine compared to phenylephrine. The routes of administration of ephedrine include oral, intramuscular and intravenous bolus.
Mechanism of Action
Ephedrine has both indirect and direct actions on the sympathetic nervous system. Its indirect effects are due to the stimulation of postganglionic sympathetic nerve endings to release norepinephrine.
As norepinephrine is a weak b-2-receptor agonist, these effects are primarily a and b-1-receptor mediated. Ephedrine's direct effects are less potent than natural catecholamines, but do provide some b-2-receptor activation.
Phenylephrine, although structurally a synthetic noncatecholamine, functions similarly to norepinephrine with direct action at the a-1-receptor. However, it is less potent, and longer acting than norepinephrine. Unlike other synthetic noncatecholamines, phenylephrine's indirect actions are minimal. Thus, phenylephrine will result in venoconstriction, which is greater than its arterial constriction, and predictably increases blood pressure by increasing both SVR and preload. Because of minimal b-2-receptor activity, phenylephrine does not cause tachycardia, but instead can cause reflex bradycardia with increasing blood pressure. 
Ephedrine
Ephedrine has become the standard vasopressor in obstetric anesthesia as a result of animal studies of the 1970s. Sol Shnider's group's investigations, using the instrumented sheep model, demonstrated that ephedrine did not cause uterine artery vasoconstriction despite releasing norepinephrine at the preganglion. 6 The result was maintenance of uterine artery blood flow and fetal pH, whereas methoxamine, mephentermine, and metaraminol tended to decrease uterine blood flow and pH.
More recent evaluations have elucidated the mechanisms contributing to the preservation of uterine blood flow by ephedrine. Eisenach initially identified a differential effect upon vascular beds of the pregnant ewe model. Ephedrine causes substantial femoral artery vasoconstriction but relatively little uterine artery vasoconstriction in the pregnant ewe compared with the nonpregnant ewe. 7 Later studies identified that nitric oxide synthase was increased in uterine artery endothelium of pregnant ewes compared with nonpregnant ewes. 8 This localized increase would mediate increased local nitric oxide production, a potent vasodilator. Given these effects, ephedrine preferentially shunts blood to the uterus during pregnancy.
With the support of these findings, ephedrine quickly became the vasopressor of choice in obstetrics. Two recent quantitative reviews summarized ephedrine's effectiveness in preventing hypotension compared with fluid boluses or expectant management. 9,10 Both reviews identified randomized clinical trials which administered intramuscular or intravenous ephedrine before or immediately after spinal anesthesia, compared with control groups receiving placebo, no intervention, or intravenous fluid boluses. The individual studies did not show a benefit with the use of ephedrine; however, the meta-analysis of their findings was significant. Ephedrine was more effective than controls in preventing maternal hypotension by almost 30% (relative risk 0.73: 95% 0.63, 0.86). However, the incidence of hypotension in the ephedrine group was still 32% to 55%.
Ephedrine Dosing
Perhaps the explanation of ephedrine's failure in up to half of the study patients was a result of inadequate dose. The minimum effective dose of ephedrine was reviewed in a paper by Lee et al, 11 which attempted to determine the dose-response from studies evaluating various doses of ephedrine. Four randomized trials compared the effect of 0, 5, 10, 15, 20, 30 mg IV ephedrine boluses given simultaneously with or immediately after spinal anesthesia for elective cesarean delivery. [12] [13] [14] [15] The dose of spinal hyperbaric local anesthesia varied slightly with one study using 10 mg of tetracaine and the rest using bupivacaine 10 to 12.5 mg. A dose-response effect was identified with reduced risk of hypotension with increasing dose of ephedrine. This benefit was balanced against the risk of maternal hypertension (usually defined as a maternal blood pressure >20% above baseline). The dose at which the authors felt the likelihood of benefit outweighed the risk of harm was 12 mg of ephedrine. This recommended dose contrasts with the commonly described dose in obstetric anesthesia texts, which recommend doses of 5 to 10 mg IV. Ephedrine's ineffectiveness at preventing hypotension in the other studies may have been the result of inadequate doses.
Another reason for ephedrine's ineffectiveness may be that the timing of administration does not coincide with the onset of anesthesiainduced hypotension. Studies administering ephedrine intramuscularly gave the medication at unspecified times prior to spinal anesthesia, 5 to 25 minutes before the spinal, or after the administration of spinal anesthesia. None of the studies confirmed pharmacologic activity of the drug before the administration of spinal anesthesia and its associated sympathectomy and hypotension. Ephedrine was administered either as a bolus or as an infusion. Intravenous infusion rates ranged between 0.5 and 5 mg/min, and bolus doses were between 5 and 30 mg preceding or after spinal anesthesia. Again, the activity of ephedrine likely lagged behind the onset of those physiologic changes leading to hypotension. It is possible that the timing of ephedrine administration has not been optimized. I have not identified any study, which attempted to increase maternal blood pressure with ephedrine before spinal anesthesia. Obviously concerns over this methodology would have to be considered, but spinal-induced hypotension and its consequences are not inconsequential.
Ephedrine and Umbilical Arterial Acidosis
Ephedrine has been associated with lower umbilical artery (UA) pH when compared with other vasopressors, such as phenylephrine, or to controls. 13, 16, 17 The difference in mean umbilical arterial pH values was approximately -0.03, with the range of mean pH in ephedrine groups between 7.18 (SD 0.13) and 7.27 (SD 0.04). Although the difference is statistically significant, the clinical relevance has yet to be determined. No study has shown a difference in long-term neonatal outcome. Only surrogate outcomes have been measured. However, 2 important predictors of poor outcomes for the neonate are UA pH below 7.2 and UA negative base deficit lower than 12.
Cooper et al 18 found a greater number of neonates with an UA pH of less than 7.2 and NganKee et al 19 found that ephedrine use was associated with a lower negative base excess compared with phenylephrine.
Riley 20 hypothesized the pathophysiology of ephedrine's association with lower UA pH in 2004. He was concerned by accumulating evidence that ''doses of ephedrine large enough to maintain homeostasis after the induction of spinal anesthesia may be detrimental to the fetus.'' He suggested that ephedrine, which crosses the placenta, led to increased fetal metabolic activity and subsequent reductions in fetal arterial pH. Presuming that much of the argument against ephedrine is based upon its effect on UA pH or umbilical base deficit, we must define a deleterious pH and base deficit. What are the implications of an UA pH of 7.20, 7.10, or 7.00, and when should we be concerned that acidotic intrapartum conditions are responsible for long-term, deleterious neonatal outcomes? In 1999, a consensus paper of the American, Canadian, and Australian obstetric societies defined the evidence required to identify a significant intrapartum asphyxial event severe enough to be cause neonatal neurologic injury. 21 The committee concluded that an intrapartum asphyxial event was associated with a significant metabolic acidosis, defined as an UA pH <7.00 and base deficit >12 mmol/L. In the studies to date, which have been carried out on healthy, uncomplicated elective cesareans, ephedrine use has caused a reduction in umbilical arterial pH primarily because of elevated fetal CO2 levels, indicating a respiratory acidosis. Numerous pediatric and obstetric papers have identified that respiratory acidosis alone is not associated with newborn complications. 22, 23 It seems that ephedrine is not deleterious to the uncompromised fetus. Ephedrine's effect on the compromised fetus is unknown.
If maternal ephedrine increases fetal catecholamines and metabolic activity, similar to the effect of labor, might this be beneficial? The incidence of transient tachypnea of the newborn (TTN) is significantly reduced amongst babies born following a labor compared with babies born at elective cesarean delivery. This concept was tested in a blinded, randomized clinical trial evaluating the effectiveness of terbutaline administered to mothers 2 hours before an elective cesarean delivery. 24 The authors hypothesized that the b-adrenergic stimulation of terbutaline would simulate labor and improve respiratory function and glucose homeostasis in the newborn. Twenty-five babies were studied, after 13 mothers received terbutaline and 12 received saline placebo. Initial respiratory rates of the babies in the terbutaline group were significantly lower than the placebo group, and serum glucose levels were maintained over the first 2 hours at a higher level in the terbutaline group. Babies of mothers who received terbutaline also had significantly lower airway resistance and higher lung compliance than controls, as measured by pneumotachometer. Two babies in the control group were diagnosed with TTN. However, the UA base deficit was significantly higher for the treatment group, with a BE of -5.2 compared with -2.7 for the control group.
The last issue to address is what is the relative importance of ephedrine's contribution to UA pH changes compared with other variables. A retrospective study of all elective cesarean deliveries performed under hyperbaric bupivacaine spinal anesthesia identified 12 explanatory variables and assessed their contribution towards the prediction of final UA pH. 25 The explanatory variables included patient demographics (age, weight, height, neonatal birth weight), anesthesia-related information (block height, use of prehydration, vasopressor used, maximum decrease in systolic pressure, and length of hypotension) and relevant obstetric information (induction to delivery time, skin incision to delivery time, uterine incision to delivery time). Each variable was evaluated in a multivariate linear regression model, a statistical technique that allows for evaluation of each variable's effect adjusting for the other variables effect on the outcome, UA pH. The final predictive model concluded that the important variables to predict the UA pH were whether ephedrine was used, the length of uterine incision to delivery time, the maximum decrease in systolic pressure in mm Hg, and the duration of hypotension in minutes. An interaction term was identified in the model, between ephedrine use and duration of hypotension, indicating that the women receiving ephedrine had a further deleterious effect depending upon the duration of hypotension.
The final mathematical model to predict UA pH in this population of healthy women under spinal anesthesia was:
UA pH = 7.413 to 0.042 (if ephedrine used) -0.014 Â duration of hypotension in minutes (if ephedrine used) -0.001 Â maximum decrease in systolic arterial pressure in mm Hg -0.0002 Â uterine incision to delivery time+ 0.0002 Â duration of hypotension in minutes.
Although this formula seems overwhelming, its applicability can be seen using a case of extreme pathophysiology: a woman for elective cesarean delivery under spinal anesthesia has a significant reduction of systolic arterial pressure of 40 mm Hg, who then receives ephedrine and has a hypotensive episode of 5 minutes and then experiences a longer than usual uterine incision to delivery time of 32 seconds. In this case, the above formula predicts the resulting UA pH to be 7.25. This demonstrates that there is a large reserve for protecting the fetus from acidosis. [26] [27] [28] Ephedrine, with its longer duration of action, still has a role in obstetric anesthesia to prevent or treat spinal-induced hypotension when given in an appropriate dose. The optimal method to administer ephedrine, whether combined with other vasopressor therapy or nonmedication therapy, awaits future study. 
Phenylephrine

Concerns With Using a-1-agonist Agents
Standard obstetric anesthesia textbooks up until the 1990s condemned the use of a-1-agonists in the treatment or prevention of maternal hypotension. These recommendations were based on sheep studies, which detailed drastic reductions in uterine blood flow after the administration of methoxamine, metaraminol, or phenylephrine. 29 However, in the 1990s clinical researchers reported on the effectiveness of phenylephrine in treating spinal anesthesia-induced hypotension. 30 The incentive to evaluate this vasopressor arose from the failure of ephedrine when used in the recommended 5 to 10 mg IV bolus doses, and a desire to reduce the tachycardia elicited by ephedrine that was undesirable in some parturients.
Between 1991 and 2001, 7 studies compared ephedrine with phenylephrine among women undergoing elective cesarean delivery under spinal anesthesia. [31] [32] [33] [34] [35] [36] [37] These studies were summarized by Lee et al 38 in a quantitative review. The summary concluded that ephedrine and phenylephrine were not different in preventing or treating hypotension (refer to Table 1 ). The only difference identified in the studies was that women given phenylephrine had neonates with higher umbilical arterial pH values, by 0.03 pH units. Umbilical arterial base excess was greatest amongst neonates born to mothers receiving phenylephrine (weighted mean difference = 1.41; 95% confidence interval, 0.81-2.02).
This unexpected finding of improved neonatal parameters with phenylephrine may be explained by the lack of fetal metabolic effect as compared with ephedrine. Although UA resistance may be increased with phenylephrine, the oxygen consumption by the fetus is not, and therefore the net oxygen balance is more favorable than ephedrine. Phenylephrine has been incorporated into the clinical practice of North American obstetric anesthesiologists as the evidence grows that it is not more harmful than ephedrine. Phenylephrine has proven to be a useful, immediate remedy to maternal hypotension, and may in fact reduce the incidence of maternal intraoperative nausea and vomiting better than ephedrine. Two studies of a-agonists (metaraminol and phenylephrine) compared with ephedrine in double-blind randomized trials documented the incidence of maternal nausea and vomiting. 18, 19 The studies compared both vasopressors given as infusions with maintain systemic blood pressure at baseline values immediately after the administration of 10 to 12.5 mg spinal hyperbaric bupivacaine. Patients were repeatedly asked during the intraoperative period about nausea and the number of vomiting episodes was documented. Combining these results using a metaanalytic technique, the risk of nausea or vomiting was reduced by almost 80% in the women receiving a-agonists (refer to Fig. 2 ).
Optimal Method of Phenylephrine Administration
The evolution of vasopressor therapy in obstetrics has moved from the avoidance of vasoactive agents except when maternal blood pressure dropped significantly, to a philosophy that any reduction in maternal blood pressure is undesirable. Ngan Kee et al 39 compared the use of prophylactic phenylephrine with phenylephrine used only when systolic arterial blood pressure dropped Z20% from baseline. A prophylactic infusion of 100 mcg/min of phenylephrine was started immediately after the administration of 10 mg hyperbaric bupivacaine in half the study population and adjusted according to 1-minute blood pressure evaluations. The control group only received 100 mcg boluses of phenylephrine when the blood pressure dropped to r80% of baseline. The primary outcome was the UA pH, to indirectly assess fetal acid-base status. Despite almost tripling the dose of phenylephrine in the prophylactic group (median 1260 mcg; first/third quartiles 1010, 1640 mcg) compared with the treatment-only group (median 450 mcg; first/third quartiles 300, 750 mcg) fetal arterial blood gas results were no different, and only 1 neonate in each group had UA pH <7.20. The prophylactic group, however, had fewer women with hypotensive episodes (23%) compared with the treatment group (88%). The number of hypotensive episodes was greater and the minimum systolic arterial pressure was lower amongst women in the treatment-only group. Phenylephrine was shown to have beneficial effects when given before the development of hypotension without compromising the balance of fetal oxygen demand/delivery.
A recent randomized clinical trial examined the maternal and neonatal effects of maintaining maternal blood pressure within 80%, 90%, or 100% of baseline levels using a phenylephrine infusion. 40 Using phenylephrine 100 mcg/mL infused at initial rates of 100 mcg/ min, the investigators adjusted the dose depending upon whether blood pressure was kept within the assigned group's range. The primary outcome was the difference in UA pH between the 3 groups, and secondary outcomes of the incidence of hypotension, reactive hypertension, nausea, and vomiting. Despite an almost 2-fold increase in the mean phenylephrine dose administered, women in the 100% baseline group had fewer episodes of nausea or vomiting (4% vs. 16%, 40%) and their neonatal mean umbilical arterial pH was higher (7.32 ± 0.04 vs. 7.30 ± 0.03 for both other groups). The unpleasant symptoms of hypotension are better controlled with tight control of blood pressure using aggressive vasopressor administration. Maximizing uterine artery perfusion after the sympathectomy of spinal anesthesia may be more important in maintaining uterine blood flow and fetal well being than previously understood.
Our concern with a-1-agonists' vasoconstrictive effects on the uterine artery has distracted us from their effects across different vascular beds. In an elegant study of pregnant and nonpregnant sheep, Magness et al 41 demonstrated that the pregnant uterine artery was less responsive to a-1-agonist stimulation than the nonpregnant uterine artery. Figure 3 illustrates the relative changes in pregnant and nonpregnant uterine vascular resistance, SVR, mean arterial pressure, Phenylephrine appears to have survived the period of intense suspicion and concern over its use in obstetric anesthesia. It is reliable in its effect, although short-acting, and its effect on the fetus appears to be even less than that of ephedrine.
Combination Therapy
There are 3 recent publications which examined the use of combination vasopressor therapy, 18, 42, 43 and one which examined the use of intravenous fluid administration with vasopressor therapy. 44 
Combination Vasopressor Therapy
The 3 studies evaluating combined vasopressor therapy used ephedrine and phenylephrine, but compared slightly different regimes. Mercier et al 42 compared the prophylactic capabilities of an ephedrine and phenylephrine infusion (2 mg/min+ 10 mcg/min) to an ephedrine infusion (2 mg/min) alone. The vasopressor infusion was begun at 40 mL/h following a spinal bupivacaine dose of 11 mg (with sufentanil and morphine) and adjusted up or down depending upon maternal blood pressure measured every minute. Their primary outcome of interest was the incidence of maternal hypotension defined as a systolic blood pressure less than 100 mm Hg or <80% of the baseline measurement. The incidence of hypotension was halved in the phenylephrine/ephedrine group (37%) compared with the ephedrine group (75%). One would expect these findings given the combination group received larger doses of vasopressor therapy. A criticism of this study was that patients in the ephedrine only group should have received a larger, equipotent dose.
Loughrey et al 43 compared intravenous boluses of ephedrine and phenylephrine (10 mg+ 40 mcg) to an ephedrine bolus alone (10 mg) given simultaneously during spinal administration of 12 mg of bupivacaine with fentanyl and morphine. Again the patients in the control group did not receive an equipotent dose of vasopressor as the patients in the combination therapy group. The primary outcome was maternal hypotension, defined as a drop in systolic blood pressure of >20% from baseline or below 100 mm Hg occurring during 1-minute interval measurements. The incidence of hypotension in this study did not differ between the 2 groups with a 95% incidence in the combination group and an 80% incidence in the ephedrine only group. The authors concluded that the initial bolus doses were inadequate in both groups, and that perhaps an infusion method may have been more efficient in preventing hypotension.
Cooper et al 18 compared 3 different infusion regimes of vasopressors; phenylephrine 100 mcg/mL, ephedrine 3 mg/mL, and combination of 50 mcg/mL phenylephrine with 1.5 mg/mL ephedrine started at 20 mL/h after the administration of spinal anesthesia. The bupivacaine dose was 12.5 mg with added fentanyl. This study's primary outcome was different, in that the authors were interested in the incidence of fetal acidosis (defined as UA pH <7.20). There was a greater incidence of fetal acidosis amongst the ephedrine only group (21/50; 42%) compared with either the phenylephrine only group (1/48; 2%) or the combination therapy group (1/47; 2%). However, the incidence of maternal hypotension (defined as systolic pressure <80% of baseline) was not different between the groups: 48% for phenylephrine only group, 68% for ephedrine group, and 57% for the combination therapy group.
Reflecting upon these studies, the administration of vasopressor drugs by infusion as close to the time of spinal anesthesia administration as possible appears to be helpful in reducing the incidence of hypotension. However, significant maternal hypotension still occurs in almost half of the women receiving combined ephedrine and phenylephrine infusions. An alternative solution investigated has been combining vasopressor therapy with other modalities used to reduce the incidence of hypotension.
Combination Vasopressor Therapy and Intravenous Hydration
In 2005, Ngan Kee et al 44 examined the benefits of simultaneous administration of intravenous fluids with vasopressor administration. Patients were randomized to receive either a rapid infusion of 2.0 L of warmed Ringer's lactate solution or an infusion rate of Ringer's lactate to keep the vein open following 10 mg spinal bupivacaine and fentanyl. All women in the study received a phenylephrine infusion starting at a dose of 100 mcg/min after the administration of the spinal anesthetic. The study's primary outcome was the incidence of maternal hypotension. Maternal systolic blood pressure was measured every minute after spinal anesthesia and the phenylephrine infusion was altered depending upon effect. With the technique of high dose phenylephrine infusion combined with a rapid intravenous cohydration, the authors reduced the incidence of hypotension to less than 2% (1/53) compared with an incidence of 28% amongst those receiving the phenylephrine infusion alone (15/53). 
Conclusions
With adequate dosages of bupivacaine for spinal anesthesia, pregnant women will develop significant, unpleasant hypotension if anesthesia vigilance and appropriate response are lacking. Nonpharmacologic methods can reduce the incidence of hypotension; however, the incidence of hypotension is still substantial, requiring vasopressor rescue.
Ephedrine has been recommended in the past as the most appropriate vasopressor agent for pregnant patients. However, human research has identified its association with lower UA pH values, likely due to increased fetal metabolic activity. The benefits of ephedrine include its longer length of action compared to phenylephrine, and its chronotropic effect. However, the reliability of effect requires using a dose of ephedrine between 10 to 15 mg by intravenous bolus, or infusion of >2 mg/min. Among academic obstetric anesthetists, ephedrine's use has declined and has often been relegated to a second line agent. Phenylephrine, on the other hand, has entered a renaissance period with the recognition that the vasoconstriction it causes does not have a detrimental effect on placental perfusion, and instead is a reliable and fast agent to prevent or treat maternal hypotension. Its only drawbacks are its short duration of action, necessitating infusion therapy, and its predictable carotid sinus reflex effect resulting occasionally in profound maternal bradycardia. The combination of phenylephrine with ephedrine to take advantage of both agents' effects at reduced dosages appears to work best when administered as an infusion. What is left to determine is whether phenylephrine's potent vasoconstricting effects are significant when given to a woman with a compromised fetal-placental unit.
Perhaps the most interesting study to date identified the original concept of intravenous fluid preloading has a place when administered rapidly at the same time as the spinal anesthetic and with a prophylactic vasopressor infusion. Future development of sophisticated computerdriven devices will reduce the difficulties of attempting to administer these therapies with spinal anesthesia. 
